Trastuzumab Plus Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer
Status:
Completed
Trial end date:
2004-07-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver
tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use
different ways to stop tumor cells from dividing so they stop growing or die. Combining
monoclonal antibody therapy with chemotherapy may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of the monoclonal antibody trastuzumab
plus carboplatin and paclitaxel in treating patients who have advanced non-small cell lung
cancer.